Keyphrases
Tumor
100%
Liver Cancer
100%
Tyrosine Kinase Inhibitor
100%
Immunological Response
100%
Inhibitor Resistant
100%
Hepatocellular Carcinoma
66%
Tumor Necrosis Factor-α
33%
Malignancy
33%
Protective Effect
33%
Poor Response
33%
Hepatocellular Carcinoma Cells
33%
Oxidative Stress
33%
Pharmacological Inhibitors
33%
Hepatocellular Carcinoma Patients
33%
Advanced Hepatocellular Carcinoma
33%
Therapeutic Approaches
33%
Treatment Scheme
33%
Sorafenib
33%
Intrinsic Mechanism
33%
Mitochondrial Damage
33%
Lenvatinib
33%
Immune Checkpoint Inhibitors
33%
Immunogenic Cell Death
33%
Stimulator of Interferon Genes (STING)
33%
Anti-PD-1
33%
Tyrosine Kinase Inhibitor Therapy
33%
Sorafenib-resistant Hepatocellular Carcinoma
33%
Immune Checkpoint Inhibitor Treatment
33%
Tyrosine Kinase Inhibitor Treatment
33%
Type I Interferon Signaling
33%
Anti-PD-1 Therapy
33%
Medicine and Dentistry
Neoplasm
100%
Hepatocellular Carcinoma
100%
Liver Cancer
100%
Tyrosine-Kinase Inhibitor
100%
Sorafenib
40%
Upregulation
40%
Immune Checkpoint Inhibitor
40%
Oxidative Stress
20%
Lenvatinib
20%
Carcinoma Cell
20%
Tumor Necrosis Factor
20%
Cancer
20%
Interferon Type I
20%
Immunogenic Cell Death
20%
Pharmacology, Toxicology and Pharmaceutical Science
Liver Cell Carcinoma
100%
Protein Tyrosine Kinase Inhibitor
100%
Liver Cancer
100%
Neoplasm
100%
Immune Checkpoint Inhibitor
40%
Sorafenib
40%
Interferon Type I
20%
Immunogenic Cell Death
20%
Lenvatinib
20%
Tumor Necrosis Factor
20%